Kymera TherapeuticsvsEli Lilly and Company

KYMR and LLY stock compared: price, dividend, valuation and results, from SEC filings.

KYMR

Kymera Therapeutics, Inc.

$121.13

Value $9.9B

-0.32%
KYMR's page

LLY

Eli Lilly and Company

$1,382.75

Value $1.30T

-2.32%
LLY's page

Kymera Therapeutics (KYMR) has a market value of $9.9B and Eli Lilly and Company (LLY) $1.30T. Over the last year, with dividends, KYMR moved +89.0% and LLY +36.2%. Dividend yield: KYMR none, LLY 0.46%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KYMR$9.9B

    LLY$1.30T

    LLY is 132 times KYMR

  • Revenue, 12 months

    KYMR$102M

    LLY$86.5B

    LLY is 846 times KYMR

  • Net income, 12 months

    KYMR-$349M

    LLY$27.6B

  • Operating margin

    KYMR-396.0%

    LLY–

  • ROIC

    KYMR-22.3%

    LLY35.5%

    57.7 points apart

  • P/E

    KYMR–

    LLY47.3

  • Dividend yield

    KYMR0.0%

    LLY0.5%

    0.5 points apart

  • 5-year return

    KYMR+93.5%

    LLY+452.8%

    359.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KYMR+93.5%

LLY+452.8%

020040060020222023202420252026
Returns by period
PeriodKYMRWith dividendsLLYWith dividends
1 year since November 17, 2025+89.0%Price +89.0%+36.2%Price +35.3%
3 years since November 17, 2023+523.4%+84.0% a yearPrice +523.4%+138.4%+33.6% a yearPrice +133.7%
5 years since November 17, 2021+93.5%+14.1% a yearPrice +93.5%+452.8%+40.8% a yearPrice +429.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KYMRKymera TherapeuticsLLYEli Lilly and Company

Valuation

KYMRLLY
Valuation
Price$121.13$1,382.75
Market value$9.9B$1.30T
Enterprise value (EV)$8.9B$1.35T
P/E–47.3
P/E, 5-year median–49.9
P/B6.132.4
EV/EBIT–38.8
Free cash flow yield–1.5%

Results and growth

KYMRLLY
Results and growth
Revenue, 12 months$102M$86.5B
Net income, 12 months-$349M$27.6B
Free cash flow, 12 months-$289M$19.7B
Earnings per share, 12 months-$3.63$30.81
Revenue growth, year on year-16.7%44.7%
Revenue growth a year, past+2.9%over 5 years+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

KYMRLLY
Margins and returns on capital
Gross margin0.0%83.6%
Operating margin-396.0%–
Net margin-341.8%31.9%
ROIC-22.3%35.5%
ROE-24.3%88.6%

Balance sheet

KYMRLLY
Balance sheet
Cash$971M$4.9B
Total debt$77M$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

KYMRLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KYMR or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Kymera Therapeutics or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.30T) is about 131.9 times Kymera Therapeutics ($9.9B), at today's prices.

How did KYMR and LLY stock do over the last 5 years?

Since November 17, 2021, KYMR's price moved +93.5% and LLY's +429.4%. With dividends: KYMR +93.5% (+14.1% a year), LLY +452.8% (+40.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, KYMR or LLY?

The dividend yield at today's price is none for Kymera Therapeutics and 0.46% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Kymera Therapeutics or Eli Lilly and Company?

Over the last twelve months, the net margin was -341.8% for Kymera Therapeutics and 31.9% for Eli Lilly and Company, and the operating margin -396.0% and –. Revenue was $102M and $86.5B.

Which is the better investment, Kymera Therapeutics or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.